Literature DB >> 29122359

Prognostic impact of RITA expression in patients with anal squamous cell carcinoma treated with chemoradiotherapy.

Franz Rödel1, Kerstin Steinhäuser2, Nina-Naomi Kreis2, Alexandra Friemel2, Daniel Martin3, Ulrike Wieland4, Margret Rave-Fränk5, Panagiotis Balermpas6, Emmanouil Fokas6, Frank Louwen2, Claus Rödel6, Juping Yuan7.   

Abstract

BACKGROUND: RBP-J interacting and tubulin-associated protein (RITA) has been identified as a negative regulator of the Notch signalling pathway and its deregulation is involved in the pathogenesis of several tumour entities. RITA's impact on the response of anal squamous cell carcinoma (SCC) to anticancer treatment, however, remains elusive.
MATERIALS AND METHODS: In our retrospective study immunohistochemical evaluation of RITA was performed on 140 pre-treatment specimens and was correlated with clinical and histopathologic characteristics and clinical endpoints cumulative incidence of local control (LC), distant recurrence (DC), disease-free survival (DFS) and overall survival (OS).
RESULTS: We observed significant inverse correlations between RITA expression and tumour grading, the levels of HPV-16 virus DNA load, CD8 (+) tumour infiltrating lymphocytes and programmed death protein (PD-1) immunostaining. In univariate analyses, elevated levels of RITA expression were predictive for decreased local control (p = 0.001), decreased distant control (p = 0.040), decreased disease free survival (p = 0.001) and overall survival (p < 0.0001), whereas in multivariate analyses RITA expression remained significant for decreased local control (p = 0.009), disease free survival (p = 0.032) and overall survival (p = 0.012).
CONCLUSION: These data indicate that elevated levels of pretreatment RITA expression are correlated with unfavourable clinical outcome in anal carcinoma treated with concomitant chemoradiotherapy.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anal cancer; HPV-16; Prognostic marker; RITA

Mesh:

Substances:

Year:  2017        PMID: 29122359     DOI: 10.1016/j.radonc.2017.10.028

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

1.  Prognostic factors for patients with anal cancer treated with conformal radiotherapy-a systematic review.

Authors:  Alexandra Gilbert; Ane L Appelt; Stelios Theophanous; Robert Samuel; John Lilley; Ann Henry; David Sebag-Montefiore
Journal:  BMC Cancer       Date:  2022-06-03       Impact factor: 4.638

2.  RITA modulates cell migration and invasion by affecting focal adhesion dynamics.

Authors:  Samira Catharina Hoock; Andreas Ritter; Kerstin Steinhäuser; Susanne Roth; Christian Behrends; Franz Oswald; Christine Solbach; Frank Louwen; Nina-Naomi Kreis; Juping Yuan
Journal:  Mol Oncol       Date:  2019-08-06       Impact factor: 6.603

3.  RITA Is Expressed in Trophoblastic Cells and Is Involved in Differentiation Processes of the Placenta.

Authors:  Julia Maria Wildner; Alexandra Friemel; Lukas Jennewein; Susanne Roth; Andreas Ritter; Cornelia Schüttler; Qi Chen; Frank Louwen; Juping Yuan; Nina-Naomi Kreis
Journal:  Cells       Date:  2019-11-21       Impact factor: 6.600

4.  RITA1 drives the growth of bladder cancer cells by recruiting TRIM25 to facilitate the proteasomal degradation of RBPJ.

Authors:  Huancheng Tang; Xiangdong Li; Lijuan Jiang; Zefu Liu; Lei Chen; Jiawei Chen; Minhua Deng; Fangjian Zhou; Xianchong Zheng; Zhuowei Liu
Journal:  Cancer Sci       Date:  2022-06-28       Impact factor: 6.518

5.  Assessment of circularized E7 RNA, GLUT1, and PD-L1 in anal squamous cell carcinoma.

Authors:  Bahir H Chamseddin; Eunice E Lee; Jiwoong Kim; Xiaowei Zhan; Rong Yang; Kathleen M Murphy; Cheryl Lewis; Gregory A Hosler; Suntrea T Hammer; Richard C Wang
Journal:  Oncotarget       Date:  2019-10-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.